Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reverse HER2-negative Immune Resistant Breast Cancer

NCT06731140 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06731140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06731140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reverse HER2-negative Immune Resistant Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
February 12, 2025
Completion date
October 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 negative breast cancer